Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has begun production of hydroxychloroquine (HCQ), a treatment currently under investigation for COVID-19.   Sterling will be manufacturing the active pharmaceutical ingredient (API) with the finished product being manufactured and supplied by Accord Healthcare.   The UK’s current supply of HCQ is sourced from overseas, primarily as a result of economic pressures driving production to lower cost manufact...